<DOC>
	<DOCNO>NCT00005986</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness chemotherapy filgrastim follow peripheral stem cell transplantation treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy , Filgrastim Peripheral Stem Cell Transplantation Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Assess clinical outcome , survival , morbidity transplantation therapy patient chronic myelogenous leukemia treat high dose chemotherapy filgrastim ( G-CSF ) follow autologous retrovirally transduced peripheral blood stem cell ( PBSC ) transplantation . - Determine whether prim treatment increase fraction benign Philadelphia chromosome ( Ph ) negative hematopoietic progenitor PBSC reduce incidence persistent recurrent leukemia autologous transplantation mobilize PBSC patient . - Assess whether retroviral transduction mobilize PBSC progenitor determine contribution malignant Ph positive progenitor contaminate graft relapse transplantation patient . - Determine whether prim treatment expand benign progenitor population PBSC collection patient . OUTLINE : In prim phase , patient receive cyclophosphamide IV 2 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SQ ) daily begin day 4 continue completion leukapheresis . Peripheral blood stem cell ( PBSC ) harvest 4-7 time day 10 21 begin blood count recover ( CD34+ cell select 2 PBSC collection transduce LN NEO virus prior cryopreservation ) . In transplant phase , patient receive prior radiotherapy receive cyclophosphamide IV 2 hour daily day -7 -6 total body irradiation day -4 -1 . Autologous PBSC LN NEO transduce CD34+ cell reinfused day 0 . Patients also receive G-CSF IV daily begin day 0 continue blood count recover . Patients receive prior radiotherapy receive oral busulfan every 6 hour day -10 -7 cyclophosphamide IV daily day -6 -3 . Autologous PBSC LN NEO transduce CD34+ cell reinfused day 0 . Patients also receive G-CSF IV daily begin day 0 continue blood count recover . All patient receive interferon alfa SQ daily disease progression unacceptable toxicity . Patients follow 3 week ; 3 , 6 , 9 , 12 , 18 , 24 month ; annually thereafter . PROJECTED ACCRUAL : A total 4-26 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic accelerate phase chronic myelogenous leukemia Philadelphia chromosome positive OR BCR/ABL rearrangement No blast crisis post blast crisis No moderate severe fibrosis define bilateral trephine biopsy Not eligible refused participate allogeneic marrow transplant protocols No splenomegaly ( umbilicus ) respond chemotherapy and/or radiotherapy PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Karnofsky 90100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Normal organ function ( except bone marrow ) PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interferon alfa allow Chemotherapy : Prior hydroxyurea allow At least 2 month since prior busulfan ( time PBSC harvest ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>